LANGUAGE
KOREANENGLISH
LOCATION
  • COMPANY
  • R&D
    • R&D Institute
    • GMP Manufacturing Facility
    • Clinical Development Status
    • Publications
  • PRODUCTS
    • 1st Generation
      • Overview
      • CARTISTEM®
      • PNEUMOSTEM®
    • 2nd Generation
      • Overview
      • SMUP-IA-01
      • SMUP-IV-01
    • R&D Inquiries
  • BUSINESS
    • CELLTREE Cord Blood Bank
    • MOVITA Nutritional Supplements
  • IR
    • Stock Information
    • Disclosure
    • Financial Information
    • IR Inquiries
  • PR
    • MEDIPOST on Media
    • Corporate Brochure
  • CONTACT US
    • Customer Center
    • R&D Inquiries
    • IR Inquiries
MEDIPOST’s Cord Blood Bank, CELLTREE Evaluated ‘Suitable’ in All Areas by the Ministry of Health and Welfare
2016/02/12
CORD BLOOD BANK

MEDIPOST’s cord blood bank, CELLTREE was evaluated ‘suitable’ in all areas including the safety and quality of cord blood by the Ministry of Health and Welfare.

In the ‘Regular Cord Blood Management Evaluation’ jointly conducted by the Ministry of Health and Welfare, Korea Centers for Disease Control and Prevention and outside experts, MEDIPOST was notified that it has complied with the strict standards of the evaluation.

The ‘Regular Cord Blood Management Evaluation’ is conducted biannually, evaluating 50 areas including the records of collection and disposal of cord blood, facilities, personnel, safety management, quality management and advertisement related to maintaining a cord blood bank.

VIEW LIST

Related News

MEDIPOST starts cord blood-derived immune cell therapy development with the establishment of its subsidiary “IMMUNIQUE”2021/04/02
Star Actress Choi Jiwoo Stores Her Baby’s Umbilical Cord Blood Unit at MEDIPOST’s CELLTREE2020/05/18
Longer-Term Storage of Cord Blood Gains Popularity Over 20,000 Cumulative Cases at CELLTREE2020/04/29
Korean Star Couple Rain and Kim Tae-hee Bank Baby’s Cord Blood in MEDIPOST2017/10/25

Latest News

MEDIPOST Enhances its Partnership with Canada’s OmniaBio in Collaboration for the CMDO Business of OmniaBio’s All-Around Cell and Gene Therapy.
2022/12/01
Medipost to launch a CDMO business for cell and gene therapy products in Korea based on 20 years of research and production knowledge
2022/10/17
Canada’s OmniaBio, MEDIPOST affiliate begins CDMO cGMP for cell gene therapy
2022/10/07
MEDIPOST’s 5-year follow-up of phase 3 clinical trial patients receives 2021 OJSM award
2022/07/18
Medipost enters North American market by acquiring OmniaBio, a CDMO company with cell and gene therapy products
2022/05/31

Contacts

21, Daewangpangyo-ro 644, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea MEDIPOST Co., Ltd.
TEL : 82-2-3465-6677

CS CENTER
ONLINE INQUIRY

Latest News

·
MEDIPOST Enhances its Partnership with Canada’s OmniaBio in Collaboration for the CMDO Business of OmniaBio’s All-Around Cell and Gene Therapy.2022.12.01
·
Medipost to launch a CDMO business for cell and gene therapy products in Korea based on 20 years of research and production knowledge2022.10.17
·
Canada’s OmniaBio, MEDIPOST affiliate begins CDMO cGMP for cell gene therapy2022.10.07
·
MEDIPOST’s 5-year follow-up of phase 3 clinical trial patients receives 2021 OJSM award2022.07.18
·
Medipost enters North American market by acquiring OmniaBio, a CDMO company with cell and gene therapy products2022.05.31

Family Site

· CELLTREE Cord Blood Bank
· MOVITA Nutritional Supplements

· LOCATION
· PRIVACY POLICY

©Copyright – The Future of Biotechnology, MEDIPOST